866-997-4948(US-Canada Toll Free)

Global Infliximab and biosimilar Market Insights, Forecast to 2025

Published By :

QYResearch

Published Date : Nov 2018

Category :

Pharmaceutical

No. of Pages : 113 Pages

Infliximab (trade names Remicade among others) is a chimeric monoclonal antibody biologic drug that works against tumor necrosis factor alpha (TNF-) and is used to treat autoimmune diseases.
In 2017, the global Infliximab and biosimilar market size was xx million US$ and is forecast to xx million US in 2025, growing at a CAGR of xx% from 2018. The objectives of this study are to define, segment, and project the size of the Infliximab and biosimilar market based on company, product type, application and key regions.

This report studies the global market size of Infliximab and biosimilar in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Infliximab and biosimilar in these regions.
This research report categorizes the global Infliximab and biosimilar market by players/brands, region, type and application. This report also studies the global market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels, distributors and Porter's Five Forces Analysis.

The various contributors involved in the value chain of Infliximab and biosimilar include manufacturers, suppliers, distributors, intermediaries, and customers. The key manufacturers in the Infliximab and biosimilar include
Janssen Biotech
Merck and Co.
Pfizer

Market Size Split by Type
Infliximab
infliximab-dyyb
infliximab-abda
Market Size Split by Application
Crohn's Disease
Pediatric Crohn's Disease
Ulcerative Colitis
Rheumatoid Arthritis
Ankylosing Spondylitis
Psoriatic Arthritis
Plaque Psoriasis

Market size split by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Infliximab and biosimilar market size (value & volume) by company, key regions/countries, products and application, history data from 2013 to 2017, and forecast to 2025.
To understand the structure of Infliximab and biosimilar market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Infliximab and biosimilar manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Infliximab and biosimilar with respect to individual growth trends, future prospects, and their contribution to the total market.
To project the value and volume of Infliximab and biosimilar submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.

In this study, the years considered to estimate the market size of Infliximab and biosimilar are as follows:
History Year: 2013-2017
Base Year: 2017
Estimated Year: 2018
Forecast Year 2018 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Infliximab and biosimilar market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2017 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents

1 Study Coverage
1.1 Infliximab and biosimilar Product
1.2 Key Market Segments
1.3 Key Manufacturers Covered
1.4 Market by Type
1.4.1 Global Infliximab and biosimilar Market Size Growth Rate by Type
1.4.2 Infliximab
1.4.3 infliximab-dyyb
1.4.4 infliximab-abda
1.5 Market by Application
1.5.1 Global Infliximab and biosimilar Market Size Growth Rate by Application
1.5.2 Crohn's Disease
1.5.3 Pediatric Crohn's Disease
1.5.4 Ulcerative Colitis
1.5.5 Rheumatoid Arthritis
1.5.6 Ankylosing Spondylitis
1.5.7 Psoriatic Arthritis
1.5.8 Plaque Psoriasis
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global Infliximab and biosimilar Market Size
2.1.1 Global Infliximab and biosimilar Revenue 2016-2025
2.1.2 Global Infliximab and biosimilar Sales 2016-2025
2.2 Infliximab and biosimilar Growth Rate by Regions
2.2.1 Global Infliximab and biosimilar Sales by Regions
2.2.2 Global Infliximab and biosimilar Revenue by Regions

3 Breakdown Data by Manufacturers
3.1 Infliximab and biosimilar Sales by Manufacturers
3.1.1 Infliximab and biosimilar Sales by Manufacturers
3.1.2 Infliximab and biosimilar Sales Market Share by Manufacturers
3.1.3 Global Infliximab and biosimilar Market Concentration Ratio (CR5 and HHI)
3.2 Infliximab and biosimilar Revenue by Manufacturers
3.2.1 Infliximab and biosimilar Revenue by Manufacturers (2016-2018)
3.2.2 Infliximab and biosimilar Revenue Share by Manufacturers (2016-2018)
3.3 Infliximab and biosimilar Price by Manufacturers
3.4 Infliximab and biosimilar Manufacturing Base Distribution, Product Types
3.4.1 Infliximab and biosimilar Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Infliximab and biosimilar Product Category
3.4.3 Date of International Manufacturers Enter into Infliximab and biosimilar Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type
4.1 Global Infliximab and biosimilar Sales by Type
4.2 Global Infliximab and biosimilar Revenue by Type
4.3 Infliximab and biosimilar Price by Type

5 Breakdown Data by Application
5.1 Overview
5.2 Global Infliximab and biosimilar Breakdown Data by Application

6 North America
6.1 North America Infliximab and biosimilar by Countries
6.1.1 North America Infliximab and biosimilar Sales by Countries
6.1.2 North America Infliximab and biosimilar Revenue by Countries
6.1.3 United States
6.1.4 Canada
6.1.5 Mexico
6.2 North America Infliximab and biosimilar by Type
6.3 North America Infliximab and biosimilar by Application
6.4 North America Infliximab and biosimilar by Company

7 Europe
7.1 Europe Infliximab and biosimilar by Countries
7.1.1 Europe Infliximab and biosimilar Sales by Countries
7.1.2 Europe Infliximab and biosimilar Revenue by Countries
7.1.3 Germany
7.1.4 France
7.1.5 UK
7.1.6 Italy
7.1.7 Russia
7.2 Europe Infliximab and biosimilar by Type
7.3 Europe Infliximab and biosimilar by Application
7.4 Europe Infliximab and biosimilar by Company

8 Asia Pacific
8.1 Asia Pacific Infliximab and biosimilar by Countries
8.1.1 Asia Pacific Infliximab and biosimilar Sales by Countries
8.1.2 Asia Pacific Infliximab and biosimilar Revenue by Countries
8.1.3 China
8.1.4 Japan
8.1.5 Korea
8.1.6 India
8.1.7 Australia
8.1.8 Indonesia
8.1.9 Malaysia
8.1.10 Philippines
8.1.11 Thailand
8.1.12 Vietnam
8.1.13 Singapore
8.2 Asia Pacific Infliximab and biosimilar by Type
8.3 Asia Pacific Infliximab and biosimilar by Application
8.4 Asia Pacific Infliximab and biosimilar by Company

9 Central & South America
9.1 Central & South America Infliximab and biosimilar by Countries
9.1.1 Central & South America Infliximab and biosimilar Sales by Countries
9.1.2 Central & South America Infliximab and biosimilar Revenue by Countries
9.1.3 Brazil
9.2 Central & South America Infliximab and biosimilar by Type
9.3 Central & South America Infliximab and biosimilar by Application
9.4 Central & South America Infliximab and biosimilar by Company

10 Middle East and Africa
10.1 Middle East and Africa Infliximab and biosimilar by Countries
10.1.1 Middle East and Africa Infliximab and biosimilar Sales by Countries
10.1.2 Middle East and Africa Infliximab and biosimilar Revenue by Countries
10.1.3 GCC Countries
10.1.4 Turkey
10.1.5 Egypt
10.1.6 South Africa
10.2 Middle East and Africa Infliximab and biosimilar by Type
10.3 Middle East and Africa Infliximab and biosimilar by Application
10.4 Middle East and Africa Infliximab and biosimilar by Company

11 Company Profiles
11.1 Janssen Biotech
11.1.1 Janssen Biotech Company Details
11.1.2 Company Description
11.1.3 Sales, Revenue and Gross Margin of Infliximab and biosimilar
11.1.4 Infliximab and biosimilar Product Description
11.1.5 Recent Development
11.2 Merck and Co.
11.2.1 Merck and Co. Company Details
11.2.2 Company Description
11.2.3 Sales, Revenue and Gross Margin of Infliximab and biosimilar
11.2.4 Infliximab and biosimilar Product Description
11.2.5 Recent Development
11.3 Pfizer
11.3.1 Pfizer Company Details
11.3.2 Company Description
11.3.3 Sales, Revenue and Gross Margin of Infliximab and biosimilar
11.3.4 Infliximab and biosimilar Product Description
11.3.5 Recent Development

12 Market Opportunities, Challenges, Risks and Influences Factors Analysis
12.1 Market Opportunities and Drivers
12.2 Market Challenges
12.3 Market Risks/Restraints
12.4 Key World Economic Indicators

13 Value Chain and Sales Channels Analysis
13.1 Value Chain Analysis
13.1.1 Typical Suppliers of Key Infliximab and biosimilar Raw Material
13.1.2 Infliximab and biosimilar Customers
13.2 Sales Channels Analysis
13.2.1 Sales Channels Analysis
13.2.2 Distributors

14 Research Findings and Conclusion

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
15.3 Disclaimer

List of Table

List of Tables and Figures

Figure Picture of Infliximab and biosimilar
Figure Global Infliximab and biosimilar Production (K Units) and CAGR (%) Comparison by Types (Product Category) (2013-2025)
Figure Global Infliximab and biosimilar Production Market Share by Types (Product Category) in 2017
Figure Infliximab Product Picture
Table Major Manufacturers of Infliximab
Figure infliximab-dyyb Product Picture
Table Major Manufacturers of infliximab-dyyb
Figure infliximab-abda Product Picture
Table Major Manufacturers of infliximab-abda
Table Global Infliximab and biosimilar Market Size Growth Rate by Application 2018-2025 (K Units)
Figure Crohn's Disease
Figure Pediatric Crohn's Disease
Figure Ulcerative Colitis
Figure Rheumatoid Arthritis
Figure Ankylosing Spondylitis
Figure Psoriatic Arthritis
Figure Plaque Psoriasis
Figure Infliximab and biosimilar Report Years Considered
Figure Global Infliximab and biosimilar Market Size 2016-2025 (Million US$)
Figure Global Infliximab and biosimilar Sales 2016-2025 (K Units)
Table Global Infliximab and biosimilar Market Size by Regions 2016-2025 (K Units) & (Million US$)
Table Global Infliximab and biosimilar Sales by Regions 2016-2025 (K Units)
Table Global Infliximab and biosimilar Sales Market Share by Regions 2016-2025
Figure Global Infliximab and biosimilar Sales Market Share by Regions 2016-2025
Figure 2017 Global Infliximab and biosimilar Sales Market Share by Regions
Table Global Infliximab and biosimilar Revenue by Regions 2016-2025 (Million US$)
Table Global Infliximab and biosimilar Revenue Market Share by Regions 2016-2025
Figure Global Infliximab and biosimilar Revenue Market Share by Regions 2016-2025
Figure 2017 Global Infliximab and biosimilar Revenue Market Share by Regions
Table Global Infliximab and biosimilar Sales by Manufacturers (2016-2018) (K Units)
Table Global Infliximab and biosimilar Sales Share by Manufacturers (2016-2018)
Figure Global Infliximab and biosimilar Sales Share by Manufacturers in 2017
Table Infliximab and biosimilar Revenue by Manufacturers (2016-2018) (Million US$)
Table Infliximab and biosimilar Revenue Share by Manufacturers (2016-2018)
Figure Infliximab and biosimilar Value Share by Manufacturers in 2017
Table Global Infliximab and biosimilar Manufacturers Market Concentration Ratio (CR5 and HHI)
Table Key Manufacturers Infliximab and biosimilar Price (2016-2018) (USD/Unit)
Table Infliximab and biosimilar Manufacturers Manufacturing Base Distribution and Headquarters
Table Manufacturers Infliximab and biosimilar Product Category
Table Date of International Manufacturers Enter into Infliximab and biosimilar Market
Table Manufacturers Mergers & Acquisitions, Expansion Plans
Table Global Infliximab and biosimilar Sales by Type (2016-2025) (K Units)
Table Global Infliximab and biosimilar Sales Share by Type (2016-2025)
Figure Global Infliximab and biosimilar Sales Market Share by Type (2016-2025)
Figure Global Infliximab and biosimilar Sales Market Share by Type in 2017
Table Global Infliximab and biosimilar Revenue by Type (2016-2025) (Million US$)
Table Global Infliximab and biosimilar Revenue Share by Type (2016-2025)
Figure Global Infliximab and biosimilar Revenue Market Share by Type (2016-2025)
Figure Global Infliximab and biosimilar Revenue Market Share by Type in 2017
Table Infliximab and biosimilar Price by Type 2013-2018 (USD/Unit)
Table Global Infliximab and biosimilar Sales by Application (2016-2025) (K Units)
Table Global Infliximab and biosimilar Sales Share by Application (2016-2025)
Figure Global Sales Infliximab and biosimilar Market Share by Application (2016-2025)
Figure Global Sales Infliximab and biosimilar Market Share by Application (2016-2025)
Figure North America Infliximab and biosimilar Sales Growth Rate 2016-2025 (K Units)
Figure North America Infliximab and biosimilar Revenue Growth Rate 2016-2025 (Million US$)
Table North America Infliximab and biosimilar Sales by Countries (2016-2025) (K Units)
Table North America Infliximab and biosimilar Sales Market Share by Countries (2016-2025)
Figure 2017 North America Infliximab and biosimilar Sales Market Share by Countries
Table North America Infliximab and biosimilar Revenue by Countries (2016-2025) (Million US$)
Table North America Infliximab and biosimilar Revenue Market Share by Countries (2016-2025)
Figure 2017 North America Infliximab and biosimilar Revenue Market Share by Countries
Figure United States Infliximab and biosimilar Sales Growth Rate (2016-2025) (K Units)
Figure United States Infliximab and biosimilar Revenue Growth Rate (2016-2025) (Million US$)
Figure Canada Infliximab and biosimilar Sales Growth Rate (2016-2025) (K Units)
Figure Canada Infliximab and biosimilar Revenue Growth Rate (2016-2025) (Million US$)
Figure Mexico Infliximab and biosimilar Sales Growth Rate (2016-2025) (K Units)
Figure Mexico Infliximab and biosimilar Revenue Growth Rate (2016-2025) (Million US$)
Table North America Infliximab and biosimilar Sales by Type (2016-2025) (K Units)
Table North America Infliximab and biosimilar Sales Market Share by Type (2016-2025)
Figure 2017 North America Infliximab and biosimilar Market Share by Type
Table North America Infliximab and biosimilar Sales by Application (2016-2025) (K Units)
Table North America Infliximab and biosimilar Sales Market Share by Application (2016-2025)
Figure 2017 North America Infliximab and biosimilar Market Share by Application
Table North America Infliximab and biosimilar Sales by Company (2016-2018) (K Units)
Table North America Infliximab and biosimilar Sales Market Share by Company (2016-2018)
Figure North America Infliximab and biosimilar Sales Market Share by Company in 2017
Figure Europe Infliximab and biosimilar Sales Growth Rate 2016-2025 (K Units)
Figure Europe Infliximab and biosimilar Revenue Growth Rate 2016-2025 (Million US$)
Table Europe Infliximab and biosimilar Sales by Countries (2016-2025) (K Units)
Table Europe Infliximab and biosimilar Sales Market Share by Countries (2016-2025)
Figure 2017 Europe Infliximab and biosimilar Sales Market Share by Countries
Table Europe Infliximab and biosimilar Revenue by Countries (2016-2025) (Million US$)
Table Europe Infliximab and biosimilar Revenue Market Share by Countries (2016-2025)
Figure 2017 Europe Infliximab and biosimilar Revenue Market Share by Countries
Figure Germany Infliximab and biosimilar Sales Growth Rate (2016-2025) (K Units)
Figure Germany Infliximab and biosimilar Revenue Growth Rate (2016-2025) (K Units)
Figure France Infliximab and biosimilar Sales Growth Rate (2016-2025) (K Units)
Figure France Infliximab and biosimilar Revenue Growth Rate (2016-2025) (K Units)
Figure UK Infliximab and biosimilar Sales Growth Rate (2016-2025) (K Units)
Figure UK Infliximab and biosimilar Revenue Growth Rate (2016-2025) (Million US$)
Figure Italy Infliximab and biosimilar Sales Growth Rate (2016-2025) (K Units)
Figure Italy Infliximab and biosimilar Revenue Growth Rate (2016-2025) (Million US$)
Figure Russia Infliximab and biosimilar Sales Growth Rate (2016-2025) (K Units)
Figure Russia Infliximab and biosimilar Revenue Growth Rate (2016-2025) (Million US$)
Table Europe Infliximab and biosimilar Sales by Type (2016-2025) (K Units)
Table Europe Infliximab and biosimilar Sales Market Share by Type (2016-2025)
Figure 2017 Europe Infliximab and biosimilar Market Share by Type
Table Europe Infliximab and biosimilar Sales by Application (2016-2025) (K Units)
Table Europe Infliximab and biosimilar Sales Market Share by Application (2016-2025)
Figure 2017 Europe Infliximab and biosimilar Market Share by Application
Table Europe Infliximab and biosimilar Sales by Company (2016-2018) (K Units)
Table Europe Infliximab and biosimilar Sales Market Share by Company (2016-2018)
Figure Europe Infliximab and biosimilar Sales Market Share by Company in 2017
Figure Asia Pacific Infliximab and biosimilar Sales Growth Rate 2016-2025 (K Units)
Figure Asia Pacific Infliximab and biosimilar Revenue Growth Rate 2016-2025 (Million US$)
Table Asia Pacific Infliximab and biosimilar Sales by Countries (2016-2025) (K Units)
Table Asia Pacific Infliximab and biosimilar Sales Market Share by Countries (2016-2025)
Figure 2017 Asia Pacific Infliximab and biosimilar Sales Market Share by Countries
Table Asia Pacific Infliximab and biosimilar Revenue by Countries (2016-2025) (Million US$)
Table Asia Pacific Infliximab and biosimilar Revenue Market Share by Countries (2016-2025)
Figure 2017 Asia Pacific Infliximab and biosimilar Revenue Market Share by Countries
Figure China Infliximab and biosimilar Sales Growth Rate (2016-2025) (K Units)
Figure China Infliximab and biosimilar Revenue Growth Rate (2016-2025) (Million US$)
Figure Japan Infliximab and biosimilar Sales Growth Rate (2016-2025) (K Units)
Figure Japan Infliximab and biosimilar Revenue Growth Rate (2016-2025) (Million US$)
Figure Korea Infliximab and biosimilar Sales Growth Rate (2016-2025) (K Units)
Figure Korea Infliximab and biosimilar Revenue Growth Rate (2016-2025) (Million US$)
Figure India Infliximab and biosimilar Sales Growth Rate (2016-2025) (K Units)
Figure India Infliximab and biosimilar Revenue Growth Rate (2016-2025) (Million US$)
Figure Australia Infliximab and biosimilar Sales Growth Rate (2016-2025) (K Units)
Figure Australia Infliximab and biosimilar Revenue Growth Rate (2016-2025) (Million US$)
Figure Indonesia Infliximab and biosimilar Sales Growth Rate (2016-2025) (K Units)
Figure Indonesia Infliximab and biosimilar Revenue Growth Rate (2016-2025) (Million US$)
Figure Malaysia Infliximab and biosimilar Sales Growth Rate (2016-2025) (K Units)
Figure Malaysia Infliximab and biosimilar Revenue Growth Rate (2016-2025) (Million US$)
Figure Philippines Infliximab and biosimilar Sales Growth Rate (2016-2025) (K Units)
Figure Philippines Infliximab and biosimilar Revenue Growth Rate (2016-2025) (Million US$)
Figure Thailand Infliximab and biosimilar Sales Growth Rate (2016-2025) (K Units)
Figure Thailand Infliximab and biosimilar Revenue Growth Rate (2016-2025) (Million US$)
Figure Vietnam Infliximab and biosimilar Sales Growth Rate (2016-2025) (K Units)
Figure Vietnam Infliximab and biosimilar Revenue Growth Rate (2016-2025) (Million US$)
Figure Singapore Infliximab and biosimilar Sales Growth Rate (2016-2025) (K Units)
Figure Singapore Infliximab and biosimilar Revenue Growth Rate (2016-2025) (Million US$)
Table Asia Pacific Infliximab and biosimilar Sales by Type (2016-2025) (K Units)
Table Asia Pacific Infliximab and biosimilar Sales Market Share by Type (2016-2025)
Figure 2017 Asia Pacific Infliximab and biosimilar Market Share by Type
Table Asia Pacific Infliximab and biosimilar Sales by Application (2016-2025) (K Units)
Table Asia Pacific Infliximab and biosimilar Sales Market Share by Application (2016-2025)
Figure 2017 Asia Pacific Infliximab and biosimilar Market Share by Application
Table Asia Pacific Infliximab and biosimilar Sales by Company (2016-2018) (K Units)
Table Asia Pacific Infliximab and biosimilar Sales Market Share by Company (2016-2018)
Figure Asia Pacific Infliximab and biosimilar Sales Market Share by Company in 2017
Figure Central & South America Infliximab and biosimilar Sales Growth Rate 2016-2025 (K Units)
Figure Central & South America Infliximab and biosimilar Revenue Growth Rate 2016-2025 (Million US$)
Table Central & South America Infliximab and biosimilar Sales by Countries (2016-2025) (K Units)
Table Central & South America Infliximab and biosimilar Sales Market Share by Countries (2016-2025)
Figure 2017 Central & South America Infliximab and biosimilar Sales Market Share by Countries
Table Central & South America Infliximab and biosimilar Revenue by Countries (2016-2025) (Million US$)
Table Central & South America Infliximab and biosimilar Revenue Market Share by Countries (2016-2025)
Figure 2017 Central & South America Infliximab and biosimilar Revenue Market Share by Countries
Figure Brazil Infliximab and biosimilar Sales Growth Rate (2016-2025) (K Units)
Figure Brazil Infliximab and biosimilar Revenue Growth Rate (2016-2025) (Million US$)
Figure Argentina Infliximab and biosimilar Sales Growth Rate (2016-2025) (K Units)
Figure Argentina Infliximab and biosimilar Revenue Growth Rate (2016-2025) (Million US$)
Table Central & South America Infliximab and biosimilar Sales by Type (2016-2025) (K Units)
Table Central & South America Infliximab and biosimilar Sales Market Share by Type (2016-2025)
Figure 2017 Central & South America Infliximab and biosimilar Market Share by Type
Table Central & South America Infliximab and biosimilar Sales by Application (2016-2025) (K Units)
Table Central & South America Infliximab and biosimilar Sales Market Share by Application (2016-2025)
Figure 2017 Central & South America Infliximab and biosimilar Market Share by Application
Table Central & South America Infliximab and biosimilar Sales by Company (2016-2018) (K Units)
Table Central & South America Infliximab and biosimilar Sales Market Share by Company (2016-2018)
Figure Central & South America Infliximab and biosimilar Sales Market Share by Company in 2017
Figure Middle East and Africa Infliximab and biosimilar Sales Growth Rate 2016-2025 (K Units)
Figure Middle East and Africa Infliximab and biosimilar Revenue Growth Rate 2016-2025 (Million US$)
Table Middle East and Africa Infliximab and biosimilar Sales by Countries (2016-2025) (K Units)
Table Middle East and Africa Infliximab and biosimilar Sales Market Share by Countries (2016-2025)
Figure 2017 Middle East and Africa Infliximab and biosimilar Sales Market Share by Countries
Table Middle East and Africa Infliximab and biosimilar Revenue by Countries (2016-2025) (Million US$)
Table Middle East and Africa Infliximab and biosimilar Revenue Market Share by Countries (2016-2025)
Figure 2017 Middle East and Africa Infliximab and biosimilar Revenue Market Share by Countries
Figure GCC Countries Infliximab and biosimilar Sales Growth Rate (2016-2025) (K Units)
Figure GCC Countries Infliximab and biosimilar Revenue Growth Rate (2016-2025) (Million US$)
Figure Turkey Infliximab and biosimilar Sales Growth Rate (2016-2025) (K Units)
Figure Turkey Infliximab and biosimilar Revenue Growth Rate (2016-2025) (Million US$)
Figure Egypt Infliximab and biosimilar Sales Growth Rate (2016-2025) (K Units)
Figure Egypt Infliximab and biosimilar Revenue Growth Rate (2016-2025) (Million US$)
Figure South Africa Infliximab and biosimilar Sales Growth Rate (2016-2025) (K Units)
Figure South Africa Infliximab and biosimilar Revenue Growth Rate (2016-2025) (Million US$)
Table Middle East and Africa Infliximab and biosimilar Sales by Type (2016-2025) (K Units)
Table Middle East and Africa Infliximab and biosimilar Sales Market Share by Type (2016-2025)
Figure 2017 Middle East and Africa Infliximab and biosimilar Market Share by Type
Table Middle East and Africa Infliximab and biosimilar Sales by Application (2016-2025) (K Units)
Table Middle East and Africa Infliximab and biosimilar Sales Market Share by Application (2016-2025)
Figure 2017 Middle East and Africa Infliximab and biosimilar Market Share by Application
Table Middle East and Africa Infliximab and biosimilar Sales by Company (2016-2018) (K Units)
Table Middle East and Africa Infliximab and biosimilar Sales Market Share by Company (2016-2018)
Figure Middle East and Africa Infliximab and biosimilar Sales Market Share by Company in 2017
Table Janssen Biotech Company Details
Table Janssen Biotech Infliximab and biosimilar Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2018)
Table Janssen Biotech Recent Development
Table Merck and Co. Company Details
Table Merck and Co. Infliximab and biosimilar Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2018)
Table Merck and Co. Recent Development
Table Pfizer Company Details
Table Pfizer Infliximab and biosimilar Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2018)
Table Pfizer Recent Development
Figure GDP by Regions / Largest Economies Pie Chart in 2016
Figure G20 GDP Long-Term Forecast Total, Million US dollars, 2060
Figure G20 Gross Domestic Product (GDP)Total, US Dollars/Capita, 2016
Figure Saving Rate Total, % of GDP, 2015
Table Infliximab and biosimilar Value Chain
Table Typical Suppliers of Key Infliximab and biosimilar Raw Material
Table Infliximab and biosimilar Customers List
Table Infliximab and biosimilar Sales Channels
Table Infliximab and biosimilar Distributors List
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *